Brean Murray Carret & Co. Maintains a 'Buy' on ViroPharma (VPHM); Letter Pushes Industrial Scale Out, But Issues Appear Closer to Resolution

Brean Murray Carret & Co. maintains a 'Buy' on ViroPharma (NASDAQ: VPHM) price target of $37.00.

Brean analyst said, "VPHM received another complete response letter on their Cinryze industrial scale production line. The FDA specified three concerns related to cleaning validation, of which one will require unplanned activity to redress. Based on the company's desription of the concerns and guidance that no technical issues need to be addressed, we believe that VPHM will receive approval this year, providing the company with more than adequate capacity to supply growth beyond 2012."

For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.

Shares of ViroPharma closed at $30.50 yesterday, with a 52 week range of $14.62-$31.00.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Baird Reiterates a 'Neutral' on Onyx Pharmaceuticals (ONXX); Nexavar Miss Not Real Issue; Kyprolis Remains Focus
• Nomura Securities Maintains a 'Neutral' on Urban Outfitters (URBN); Staying Sidelined Despite Positive Q1 Surprises
• UBS Maintains a 'Buy' on JPMorgan (JPM); Patient Investors Will Be Rewarded

Create E-mail Alert Related Categories

Analyst Comments, FDA

Related Entities

Brean Murray Carret & Co.

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter